Showing results (181-190 of 247) with videos related to
Sort By:
Pageof 25
The Oncologist|August 18, 2019
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE TrialDavid R Spigel, Dianna L Shipley, David M Waterhouse, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignanciesGlen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.The Lancet. Oncology|February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human studyHoward A Burris, Ian W Flinn, Manish R Patel, et al.JAMA Oncology|December 14, 2018
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical TrialDejan Juric, Filip Janku, Jordi Rodón, et al.Journal of Neuro-Oncology|August 9, 2019
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)John D Hainsworth, Kevin P Becker, Tarek Mekhail, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2018
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell CarcinomaDavid S Hong, Kathleen Moore, Manish Patel, et al.Journal for Immunotherapy of Cancer|June 8, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignanciesAung Naing, Chia-Chi Lin, Manish R Patel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasHoward A Burris, Herbert I Hurwitz, E Claire Dees, et al.Breast Cancer Research and Treatment|October 24, 2017
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trialGabe S Sonke, Lowell L Hart, Mario Campone, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid TumorsDaniel D Von Hoff, Monica M Mita, Ramesh K Ramanathan, et al.Pageof 25